Saniona provides update on outstanding option programs
August 05 2022 - 2:00AM
Saniona provides update on outstanding option programs
PRESS RELEASE
August 5,
2022
Saniona (OMX: SANION), a clinical stage
biopharmaceutical company, today announced that
6,450,734
options have forfeited
in 2022,
leading to a reduction in
potential dilution
from 11.89% to
3.06%.
As of December 31, 2021, the company had 8,402,181 options
outstanding entitling to the subscription of maximum 8,420,812 new
shares representing a dilution of 11.89 percent.
As of July 31, 2022, the company has 1,951,447 options
outstanding entitling to the subscription of maximum 1,966,211 new
shares representing a dilution of 3.06 percent.
The company currently has several outstanding option programs.
For a description of these programs, please see note 12 in the
annual report for 2021 as well as note 5 in the interim report for
the period January – March 2022. As a result of terminations of
employees during March and April 2022, certain options previously
granted have forfeited after March 31, 2022.
For more information, please contact Thomas
Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
This information was submitted for publication, through the
agency of the contact person set out above, at 08.00 CEST on August
5, 2022.
About Saniona Saniona is a clinical-stage
biopharmaceutical company with a mission to leverage its ion
channel targeting expertise to discover, develop and deliver
innovative rare disease treatments. The company’s most advanced
product candidate, Tesomet™, has been progressed into mid-stage
clinical trials for hypothalamic obesity and Prader-Willi syndrome,
serious rare disorders characterized by severe weight gain,
disturbances of metabolic functions and uncontrollable hunger.
Saniona has developed a proprietary ion channel drug discovery
engine anchored by IONBASE™, a database of more than 130,000
compounds, of which more than 20,000 are Saniona’s proprietary ion
channel modulators. Through its ion channel expertise, Saniona is
advancing two wholly owned ion channel modulators, SAN711, SAN903.
SAN711 has successfully completed a Phase 1 clinical trial and is
positioned for the treatment of neuropathic pain conditions; SAN903
is in preclinical development for rare inflammatory, fibrotic, and
hematological disorders. Saniona is based in the Copenhagen area,
Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION).
Read more at http://www.saniona.com.
- 20220805 Saniona Options Outstanding (UK)
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Dec 2023 to Dec 2024
